Cantargia (OM:CANTA) - Aandelenkoers, Nieuws & Analyse

CANTA Overzicht aandelen

Cantargia AB (publ), een biotechnologiebedrijf, ontwikkelt op antilichamen gebaseerde behandelingen voor levensbedreigende ziekten. Meer informatie

CANTA fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 50.11% per jaar groeien

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( SEK0 )

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

De winst zal naar verwachting de komende drie jaar met gemiddeld 3.4% per jaar dalen.

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

+ 1 meer risico

Cantargia AB (publ) Concurrenten

Alzinova

OM:ALZ

SEK 340.6m

Oncopeptides

OM:ONCO

SEK 356.8m

Saniona

OM:SANION

SEK 655.6m

Curasight

NGM:CURAS

DKK 234.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Cantargia
Historische aandelenkoersen
Huidige aandelenkoers	SEK 1.82
52 Week Hoogtepunt	SEK 5.20
52 Week Laag	SEK 1.79
Bèta	1.74
11 maand verandering	-40.91%
3 maanden verandering	-53.74%
1 Jaar Verandering	-49.16%
33 jaar verandering	-90.16%
5 jaar verandering	-90.30%
Verandering sinds IPO	-79.78%

Recent nieuws en updates

Recent updates

An Intrinsic Calculation For Cantargia AB (publ) (STO:CANTA) Suggests It's 47% Undervalued

May 31

Here's Why We're Not Too Worried About Cantargia's (STO:CANTA) Cash Burn Situation

May 02

Is Cantargia (STO:CANTA) In A Good Position To Invest In Growth?

Jan 10

Rendement voor aandeelhouders

	CANTA	SE Biotechs	SE Markt
7D	-0.4%	5.8%	1.5%
1Y	-49.2%	17.5%	11.7%

Rendement versus industrie: CANTA presteerde slechter dan de Swedish Biotechs -sector, die het afgelopen jaar een rendement van 17.5 % opleverde.

Rendement versus markt: CANTA presteerde slechter dan Swedish Market, dat het afgelopen jaar een rendement van 11.7 % opleverde.

Prijsvolatiliteit

Is CANTA's price volatile compared to industry and market?
CANTA volatility
CANTA Average Weekly Movement	13.2%
Biotechs Industry Average Movement	9.4%
Market Average Movement	5.6%
10% most volatile stocks in SE Market	11.4%
10% least volatile stocks in SE Market	3.3%

Stabiele aandelenkoers: De aandelenkoers van CANTA is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 13% ) van CANTA is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen Swedish.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2009	21	Goran Forsberg	cantargia.com

Cantargia AB (publ), een biotechnologiebedrijf, ontwikkelt op antilichamen gebaseerde behandelingen voor levensbedreigende ziekten. Het bedrijf ontwikkelt CAN04 (nadunolimab), een interleukine-1 receptor accessory protein (IL1RAP) bindend antilichaam, dat zich in Fase II van het klinisch onderzoek bevindt voor de behandeling van alvleesklierkanker, niet-kleincellige longkanker en triple-negatieve borstkanker; en CAN10, een antilichaam tegen IL1RAP, dat zich in de preklinische fase bevindt voor de behandeling van auto-immuunziekten en ontstekingsziekten, waaronder systemische sclerose en myocarditis. Het ontwikkelt ook CANxx, een op IL1RAP gebaseerd antilichaamplatform.

Cantargia AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van Cantargia zich tot de beurswaarde?
CANTA fundamentele statistieken
Marktkapitalisatie	SEK 334.31m
Inkomsten(TTM)	-SEK 193.53m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-1.7x

Koers/Winstverhouding

Is CANTA overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CANTA resultatenrekening (TTM)
Inkomsten	SEK 0
Kosten van inkomsten	SEK 0
Brutowinst	SEK 0
Overige uitgaven	SEK 193.53m
Inkomsten	-SEK 193.53m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

Feb 21, 2025

Winst per aandeel (EPS)	-1.05
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde CANTA op de lange termijn?

Bekijk historische prestaties en vergelijking

CANTA Overzicht aandelen

Beloningen

Risicoanalyse

Cantargia AB (publ) Concurrenten

OM:ALZ

SEK 340.6m

OM:ONCO

SEK 356.8m

OM:SANION

SEK 655.6m

NGM:CURAS

DKK 234.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Price target decreased by 24% to kr9.67

New major risk - Revenue and earnings growth

Cantargia AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Cantargia AB (publ), Annual General Meeting, May 15, 2025

New major risk - Share price stability

Cantargia AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 169.910183 million.

Recent updates

Price target decreased by 24% to kr9.67

New major risk - Revenue and earnings growth

Cantargia AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Cantargia AB (publ), Annual General Meeting, May 15, 2025

New major risk - Share price stability

Cantargia AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 169.910183 million.

Cantargia Presents Promising Preclinical Results on Nadunolimab with Antibody-Drug Conjugates At Major Immuno-Oncology Conference

Cantargia Reports New Results from Clinical Studies Investigating Nadunolimab in Several Forms of Cancer; Supporting Ongoing Strategies

Cantargia Reports New Positive Results on Biomarkers and Safety in CAN10 Phase 1 Clinical Study

Cantargia Announces the Publication of the Results Using Nadunolimab Combination Therapy in Advanced/Metastatic Pancreatic Cancer (PDAC) in the Scientific Journal Clinical Cancer Research

Cantargia AB (publ) to Report Q1, 2025 Results on May 13, 2025

Cantargia Announces New Data from Two Clinical Studies Strongly Support Nadunolimab Efficacy After Relapse on PD1-Inhibitors

Cantargia AB (publ) Reports Timelines for Nadunolimab Clinical Trials in Leukemia and Triple Negative Breast Cancer

Can Cantargia (STO:CANTA) Afford To Invest In Growth?

Cantargia Announces Resignation of Liselotte Larsson as Chief Operating Officer

Cantargia AB (Publ) Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10

Cantargia AB (Publ) Announces Appointment of Ton Berkien as Chief Business Officer, Effective October 1, 2024

Insufficient new directors

Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy

Forecast to breakeven in 2026

New major risk - Revenue and earnings growth

We're A Little Worried About Cantargia's (STO:CANTA) Cash Burn Rate

Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition

Cantargia AB (publ) Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal

New minor risk - Share price stability

Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis

Cantargia AB (publ) Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia

Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis

Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer

Price target decreased by 7.3% to kr12.67

Forecast to breakeven in 2026

New major risk - Financial position

Cantargia AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab

Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy

Chief Executive Officer recently bought kr104k worth of stock

Cantargia Reports Phase I Clinical Progress in the CAN10 Project

Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10

Chief Executive Officer recently bought kr103k worth of stock

New major risk - Revenue and earnings growth

New major risk - Financial position

Cantargia AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Cantargia AB (publ), Annual General Meeting, May 23, 2024

New minor risk - Shareholder dilution

Cantargia Presents New Clinical Data Further Supporting Nadunolimab's Antitumor Activity and A Key Role of Its Target IL1RAP in Pancreatic Cancer

Cantargia Reports New Preclinical Data on nadunolimab Potential to Enhance Anti-Tumor Effect of Immunotherapy Presented at CRI-ENCI-AACR

Cantargia AB (publ) Announces New Nadunolimab Clinical Trial in Leukemia Financed by External US Grant

Cantargia AB (publ)Expands Clinical Pipeline and Starts Treatment in Second Program, CAN10, for Autoimmune Diseases

No longer forecast to breakeven

New major risk - Financial position

Cantargia AB (publ) to Report Q1, 2024 Results on May 21, 2024

Cantargia AB (publ) Receives Regulatory Approval to Start Phase I Clinical Trial for CAN10

New minor risk - Share price stability

Is Cantargia (STO:CANTA) In A Good Position To Deliver On Growth Plans?

Cantargia Publishes ASCO 2023 Poster on Promising Nadunolimab Efficacy in Non-Small Cell Lung Cancer

Cantargia AB (publ) Promotes David Liberg to Chief Scientific Officer

Cantargia Extends Development of Nadunolimab in Pancreatic Cancer with New Controlled Phase IIb Clinical Trial Following Strong Phase IIb Efficacy Results

We Think Cantargia (STO:CANTA) Can Afford To Drive Business Growth

Cantargia Appoints Patrik Renblad as Chief Financial Officer